259 related articles for article (PubMed ID: 14728114)
1. Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder.
Endicott J; McLaughlin TP; Grudzinski AN
J Clin Psychiatry; 2003 Dec; 64(12):1511-6. PubMed ID: 14728114
[TBL] [Abstract][Full Text] [Related]
2. A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges.
McLaughlin TP; Eaddy MT; Grudzinski AN
Clin Ther; 2004 Jan; 26(1):115-24. PubMed ID: 14996524
[TBL] [Abstract][Full Text] [Related]
3. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK; Kruzikas DT; McLaughlin TP
J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
[TBL] [Abstract][Full Text] [Related]
4. [Premenstrual dysphoric disorder (PMDD): Drug and psychotherapeutique management, a literature review].
Marais-Thomas H; Chapelle F; de Vaux-Boitouzet V; Bouvet C
Encephale; 2024 Apr; 50(2):211-232. PubMed ID: 37821319
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder.
Rendas-Baum R; Yang M; Gricar J; Wallenstein GV
Appl Health Econ Health Policy; 2010; 8(2):129-40. PubMed ID: 20175591
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of major selective serotonin-reuptake inhibitors in a managed care population.
Panzarino PJ; Xuan J
Manag Care Interface; 2001 Apr; 14(4):59-65. PubMed ID: 11339023
[TBL] [Abstract][Full Text] [Related]
7. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
[TBL] [Abstract][Full Text] [Related]
8. Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline.
Halbreich U; Kahn LS
Expert Opin Pharmacother; 2003 Nov; 4(11):2065-78. PubMed ID: 14596660
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine.
Sheehan DV; Eaddy M; Sarnes M; Vishalpura T; Regan T
J Clin Psychopharmacol; 2004 Oct; 24(5):544-8. PubMed ID: 15349013
[TBL] [Abstract][Full Text] [Related]
10. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy--results from a managed care administrative claims database.
Eaddy MT; Druss BG; Sarnes MW; Regan TS; Frankum LE
J Manag Care Pharm; 2005 Mar; 11(2):145-50. PubMed ID: 15766321
[TBL] [Abstract][Full Text] [Related]
11. Economic appraisal of citalopram in the management of single-episode depression.
Sclar DA; Skaer TL; Robison LM; Galin RS
J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):47S-54S. PubMed ID: 10507508
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants.
Poret AW; Neslusan C; Ricci JF; Wang S; Khan ZM; Kwong JW
Value Health; 2001; 4(5):362-9. PubMed ID: 11705126
[TBL] [Abstract][Full Text] [Related]
13. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
[TBL] [Abstract][Full Text] [Related]
14. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
Crown WH; Treglia M; Meneades L; White A
Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
[TBL] [Abstract][Full Text] [Related]
15. A cost-effective approach to the use of selective serotonin reuptake inhibitors in a Veterans Affairs Medical Center.
Singletary T; North DS; Weiss M; Marman G
Am J Manag Care; 1997 Jan; 3(1):125-9. PubMed ID: 10169244
[TBL] [Abstract][Full Text] [Related]
16. Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder.
Zhou ZY; Sun S; Chopra P; Zhong Y; Totev T; Signorovitch J
J Med Econ; 2015; 18(11):919-29. PubMed ID: 26121061
[TBL] [Abstract][Full Text] [Related]
17. Selective serotonin reuptake inhibitors for premenstrual syndrome.
Brown J; O' Brien PM; Marjoribanks J; Wyatt K
Cochrane Database Syst Rev; 2009 Apr; (2):CD001396. PubMed ID: 19370564
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
Vlahiotis A; Devine ST; Eichholz J; Kautzner A
J Manag Care Pharm; 2011 Mar; 17(2):123-32. PubMed ID: 21348545
[TBL] [Abstract][Full Text] [Related]
19. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders.
Panzer PE; Regan TS; Chiao E; Sarnes MW
Am J Manag Care; 2005 Oct; 11(12 Suppl):S370-9. PubMed ID: 16236019
[TBL] [Abstract][Full Text] [Related]
20. Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety.
Wan GJ; Crown WH; Berndt ER; Finkelstein SN; Ling D
Manag Care Interface; 2002 Jun; 15(6):24-30. PubMed ID: 12087603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
